Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM

Recruiting
Written By Sustainable Digital

First trial using a triple combination for WM in the US

Sites: Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Colorado Blood Cancer Institute, UT Southwestern

Accrual status: 55 of 55 patients (potential for additional patients, pending)

Highlights: Presentations at IWWM 13 and ASH 2026

Sustainable Digital

Digital Communication services, including website design, search engine optimization, social media, and content creation for nonprofit organizations, consultants, and creative entrepreneurs.

http://www.sustainabledigital.com
Previous

Loncastuximab tesirine in previously treated WM
Next

Epcoritamab in previously treated WM